Clinical Trial Search

Phase 2 N=126 Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

HIV Infections · Sexually Transmitted Diseases

Primary: Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) — 7.3; 6.7 percent of participants — p=1.00

National Institute of Allergy and Infectious… Results Jan 2012 5.6% serious AE View details

Phase 2 N=90 Comparison of Efficacy of Vitamin D and Vitamin D-calcium Fortified Yogurt Drink in Diabetic Patients

Type 2 Diabetes

Primary: Serum 25-hydroxyvitamin D — 45.6; 76.2; 78.4 nmol/L

National Nutrition and Food Technology Institute Results Jan 2012 0.0% serious AE View details

Phase 2 N=25 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS

Graft vs Host Disease · Myelodysplastic Syndromes · Leukemia

Primary: Treatment-related Mortality — 4.5 percentage of participants

National Heart, Lung, and Blood Institute (NHLBI) Results Jan 2012 100.0% serious AE View details

Phase 2 N=60 Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

Stroke, Acute

Primary: Maximally Tolerated Dose of IV Minocycline — 10 mg/kg

David Hess, MD Results Jan 2012 48.3% serious AE View details

Phase 2 N=181 Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate

Postmenopausal Women

Primary: Percent Change in Serum CTX (Type I Collagen C-telopeptide), ITT (Intent to Treat) Population — -43.20; -62.08; -65.11; -66.30 Percent Change

Warner Chilcott Results Jan 2012 1.1% serious AE View details

Phase 2 N=10 Clinical Evaluation of Direct Manufactured Prosthetic Sockets

Amputation

Primary: Hanspal Socket Comfort Score (SCS) After Initial Socket Fitting — 9; 8.7 score on scale — p=>0.4

Ohio Willow Wood Results Jan 2012 0.0% serious AE View details

Phase 2 N=187 Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)

Postherpetic Neuralgia

Primary: Primary Endpoint Will be the Change From Baseline in Average Pain Score Over the Last 7 Days of the Maintenance Phase. — -2.65; -2.22 Scores on a scale — p=0.2537

Bausch Health Americas, Inc. Results Jan 2012 4.3% serious AE View details

Phase 2 N=74 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients

Anaplastic Glioma of Brain · Glioblastoma Multiforme · Brain Cancer

Primary: 12 Month-progression-free Survival for Participants With Anaplastic Tumors — 44 percentage of participants

M.D. Anderson Cancer Center Results Jan 2012 32.4% serious AE View details

Phase 2 N=70 Treatment of Patients With Blepharitis and Facial Rosacea

Blepharitis · Meibomianitis · Dry Eye

Primary: Change in Bulbar Conjunctival Hyperemia — -0.61; -0.60 Scores on a scale — p=0.578

Galderma R&D Results Jan 2012 2.9% serious AE View details

Phase 2 N=123 A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

Coronary Artery Disease

Primary: Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose — 93.15; 31.05 Percentage

AstraZeneca Results Jan 2012 0.0% serious AE View details

Phase 2 N=195 Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

Fibromyalgia

Primary: The Primary Outcome Measure Was a Composite of Changes From Baseline in Three Co-primary Self Report Measures: Pain Visual Analog Scale (PVAS, Electronic Diaries)…

Jazz Pharmaceuticals Results Jan 2012 1.0% serious AE View details